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Abstract
Background: Endothelial progenitor cells (EPC) which
are characterised by the simulateous expression of
CD34, CD133 and vascular endothelial growth recep-
tor 2 (VEGF 2) are involved in the pathophysiology of
congestive heart failure (CHF) and their number and
function is reduced in CHF. But so far our knowledge
about the number of circulating hematopoietic stem/
progenitor cells (CPC) expressing the early hemato-
poietic marker CD133 and CD34 in CHF is spares and
therefore we determined their number and correlated
them with New York Heart Association (NYHA)
functional class.
Methods: CD34 and CD133 surface expression was
quantified by flow cytometry in the peripheral venous
blood of 41 healthy adults and 101 patients with vari-
ous degrees of CHF.
Results: CD34+, CD133+ and CD34+/CD133+ cells
correlated inversely with age. Both the number of
CD34+ and of CD34+/CD133+ cells inversely corre-
lated with NYHA functional class. The number of
CD133+ cells was not affected by NYHA class. Fur-
thermore the number of CD133+ cells did not differ
between control and CHF patients.
Conclusion: In CHF the release of CD34+, CD133+
and CD34+/CD133+ cells from the bone marrow
seems to be regulated differently. Modulating the re-
leasing process in CHF may be a tool in CHF treat-
ment.
Key words: CD34, CD133, congestive heart failure,
progenitor cell
INTRODUCTION
In the last decades our understanding of the patho-
physiology and treatment of heart failure has in-
creased substantially, especially the complex interac-
tion between the heart, peripheral circulation, humoral
and cellular system has been illuminated [1].
In the blood immature cells with the capacity to dif-
ferentiate into mature endothelial cells were detected
and are therefore called EPC. EPCs are identified by
the simultaneous expression of the characteristic sur-
facemarkers CD34, CD133 and VEGF-R2 and origi-
nate from the bone marrow. EPCs are involved in en-
dogenous endothelial repair, myocardial ischemia, my-
ocardial infarction, limb ischemia, wound healing and
atherosclerosis [2]. Patients with heart failure show en-
dothelial dysfunction, diminished NO availability and
increased endothelial apoptosis [3].
There are many experimental and clinical data
which show that in CHF the number of EPC is dimin-
ished and their function is impaired [4]. But so far
there are only few reports in CHF dealing with the
number and function of EPC precursors named circu-
lating progenitor cells (CPC) mobilized from the bone
marrow. CPC express the surfacemarkers CD34 and
CD133 and are probably the most primitive progeni-
tor cells in the circulation. CD34 is found on
hematopoietic stem cells and on mature endothelial
cells. CD133 is expressed on hematopoietic progenitor
cells but is not found on mature endothelial cells. CPC
are primitive bone marrow cells and can proliferate,
migrate, differentiate into various matures cell types
[5,6] and are proangiogenic [7].
Our study examined the number of CD34+,
CD133+ and CD34+/CD133+ cells in the peripheral
blood of healthy adults and in patients with various
NYHA functional classes.
MATERIALS AND METHODS
PATIENTS
We enroled 101 patients with New York Heart Associ-
ation (NYHA) functional class I-IV (Table 1) of our
hospital. The diagnosis of heart failure was confirmed
by clinical findings and non-invasive assessment of
cardiac function. Left ventricular ejection fraction
(LVEF) was determined by echocardiography. As a
control we used 41 healthy male blood donors (32 ± 7
years). The study was approved by the local Ethics
committee and written informed consent was obtained
from patients.
BLOOD COLLECTION
Blood collection was done on the day of admission.
All patients were supine, a 21-gauge needle was insert-
ed into an antecubital vein. A 9 ml sample of whole
blood was obtained in a EDTA plasic container (Sarst-
edt, Germany).
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Thenumberof CD34+,CD133+and CD34+/CD133+
mononuclear cells in the peripheral blood was deter-
mined by flow cytometry (FACS Calibur, Becton Dick-
inson, Heidelberg, Germany). Briefly, white blood cells
were stained with fluorescent isothiocyanate (FITC)-
conjugated CD34 antibody (clone: 581, Becton Dickin-
son/Pharmigen, Heidelberg, Germany) and a phyco-
erythrin (PE)-conjugated CD133/2 antibody (clone:
293C3, Miltenyi biotec, Bergisch Gladbach, Germany).
For negative controls, cells were stained with FITC-
and PE-conjugated mouse IgG1 (Becton Dickin-
son/Pharmingen, Heidelberg, Germany) and mouse
IgG2b (Becton Dickinson/Pharmingen, Heidelberg,
Germany).
STATISTICAL ANALYSIS
Data are expressed as mean±SD. Data were analyzed
by nonparametric tests to avoid assumptions about the
distribution of the measured variables. Bivariant re-
gression analysis is shown in graphical forms and cor-
relations were examined by Pearson correlation test. A
P-value of < 0.05 was considered significant. All sta-
tistical analyses were performed with WinSTAT.
RESULTS
Circulating CD133+, CD34+ and CD34/CD133+
cells correlate with age
In CHF we found a negative correlation of the num-
ber of CD34+, CD133+ and CD34/133+ cells with
age (CD133+: y = 1234-123x, r = 0.18, P = 0.037, n =
101; CD34+: y = 1643-12x, r = 0.17, P = 0.048, n =
101; CD34/CD133+: y = 1325-12x, r = 0.29, P =
0.001, n = 101). In CHF number of CD133+, CD34+
and CD34+/133+ cells decreases with age (Fig. 1).
Circulating CD34+, CD133+ and CD34/CD133+
cells and NYHA functional class
As shown in Figure 2 we found a small decrease of
the number of CD133+ cells in CAD in NYHA func-
tional class I and II and an increase of these cells in
NYHA III and IV compared to control. In non CAD
patients only in NYHA III we found a decrease of
CD133+ cells. Furthermore also the number of pe-
ripheral CD133+ cells was not affected significantly by
NYHA functional class.
Both numbers of CD34+andCD34+/CD133+ cells
were lower in patients than inthecontrolgroup(CD34+
in controls 2824 ± 1904 per ml and CD34+/CD133+
in controls 1164 ± 482). Furthermore the number of
CD34+ and CD34+/CD133+ cells decreased with in-
creasing NYHA functional class. Except in NYHA I
for the number of CD34/CD133+ cells we did not
find a difference between the number of CD133+,
CD34+ and CD34+/CD133+ cells in the CAD or not
CAD group indicating that the cause of CHF did not
influence peripheral progenitor cell number.
As shown in Table 2 a correlation analysis revealed
no correlation between NYHA functional class and
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Table 1. Characteristics of patients.
Variables NYHA class I NYHA class II NYHA class III NYHA class IV
N = 16 N = 25 N = 30 N = 30
Age, y 66.3 ± 8.1 66.9 ± 8.1 68.5 ± 7.6 68.7 ± 10.6
BMI, kg/m2 28.8 ± 4.5 29.0 ± 3.5 27.3 ± 4.4 29.3 ± 6.2
WBC, 103/mm3 7.1 ± 1.9 8.2 ± 1.8 8.1 ± 2.2 10.6 ± 4.1
LVEF, % 51.1 ± 14.8 37.0 ± 12.6 31.1 ± 9.8 33.8 ± 13.6
LVDd, mm 58.1 ± 9.8 64.0 ± 13.0 62.6 ± 10.2 59.6 ± 6.8
VO2 peak, ml x kg-1 x min-1 22.3 ± 10.4 19.0 ± 4.3 17.9 ± 4.8 12.0 ± 2.1
BNP, pmol/l 32.4 ± 33.2 85.7 ± 83.5 222 ± 204 474 ± 461
Underlying heart disease, n
- DCM 3 (19%) 9 (36%) 2 (7%) 3 (10%)
- Hypertension 6 (38%) 4 (16%) 8 (27%) 0 (0%)
- CAD 5 (31%) 10 (40%) 16 (53%) 20 (67%)
- Myocarditis 1 (6%) 0 (0%) 0 (0%) 0 (0%)
- others 1 (6%) 2 (8%) 4 (13%) 7 (23%)
Diabetes mellitus, n 5 (31%) 12 (48%) 13 (43%) 11 (37%)
Smoking, n 4 (25%) 4 (16%) 1 (3%) 3 (10%)
Statin, n 7 (44%) 10 (40%) 16 (53%) 18 (60%)
Values are mean ± SD or number of patients. BMI, body mass index; WBC, white blood cells; LVEF, left ventricular ejection
fraction; BNP, B-type natriuretic peptide; DCM, dilatative cardiomyopathy; CAD, coronary artery disease; NYHA, New York
Heart Association.
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the number of CD34+/CD133+ cells showed a cor-
relation with NYHA class (Y = 642-86X, r = 0.36, p =
0.006) whereas in patients without CAD either the
number of CD34+ cells (Y = 1786-341X, r = 0.47, p
= 0.0003) and the number of CD34+/CD133+ cells
(Y = 1096-200X, r = 0.49, p = 9.86E-05) correlated
with NYHA functional class.
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Fig. 1. Correlation of CD133+, CD34+ and
CD34+/ CD133+ cells (CD133+: r = 0.18, P =
0.037, n = 101; CD34+: r = 0.17, P = 0.048, n = 101;
CD34/CD133+: r = 0.29, P = 0.001, n = 101) in pa-
tients with various degrees of CHF and age.
Fig. 2. Number of peripheral CD133+, CD34+ and CD34+/
CD133+ cells in controls (C) and patients with various NYHA func-
tional classes. *p<0.05 compared to control. **p<0.05 CAD vs. no
CAD. Black bars: control. Striped bars: CAD. White bars: no CAD.
CAD: coronary artery disease.
Table 2. Association between NYHA functional class in CAD and no CAD patients and number of CD133+, CD34+ and
CD34+/CD133+ cells.
NYHA functional class Number of CD133+ cells Number of CD34+ cells Number of CD34+/133+ cells
r (p value) r (p value) r (p value)
CAD 0.17 (0.11) 0.14 (0.16) 0.36 (0.006)*
no CAD 0.04 (0.39) 0.47 (0.0003)* 0.49 (9.86E-05)*
CAD: coronary artery disease. *p<0.05.
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The first result of our study is that in CHF the periph-
eral number of CD34+, CD133+ and CD34+/
CD133+ cells decreases with increasing age. This find-
ing is in good agreement with a study published by
Shaffer et al. [8] which found that the number of
CD34+, CD133+ and CD34+/CD133+ cells is ele-
vated in younger healthy compared to older individu-
als. A similar result was reported by Scheubel et al. [9].
This group described a decreasing number of
CD34+/CD133+ cells with age in patients before by-
pass surgery and made decreasing VEGF concentra-
tions with age responsible. Because CHF alone does
not influence VEGF concentrations significantly age-
induced VEGF decrease may also be responsible in
patients with heart failure [10, 11].
The second important result of our study is the fact
that correlation analysis showed that the number of
CD34+ and CD34+/CD133+ cells decreased with in-
creasing NYHA functional class, whereas the number
of CD133+ cells was unaffected by NYHA functional
class. The first study which described a regulation of
the number of CD34+ cells was published by Val-
gimigli et al. [12]. Valgimigli found a decrease of
CD34+ cells with increasing NYHA functional class.
The fact that in NYHA I and II the number of
CD34+ cells was higher compared to control could
not be reproduced in our study. This may be due to
the fact that our control group was much younger
than the study group whereas Vaglimigli examined an
age-matched control group. Our study also confirmes
the results of Theiss et al. [11] which described higher
numbers of CD34+ and CD34+/CD133+ cells in di-
lated cardiomyopathy (DCM) than in coronary artery
disease (CAD). Different to this study we examined
the number of CD34+ and CD34+/CD133+ cells for
every NYHA functional class. Also in our study there
was a tendency to a higher number of CD34+ or
CD34+/CD133+ cells in DCM in NYHA functional
class I-III and a lower number in NYHA IV without
reaching a significant difference between CAD and no
CAD patients. That we did not see a significant differ-
ence between CAD and no CAD patients may be the
result of the small number of patients in the sub-
groups and large standard deviations. Whether aetiolo-
gy of CHF involves EPC number is still not known
because there is also a study by Michowitz et al. show-
ing that aetiology did not influence EPC number mea-
sured by EPC-colony-forming units [13]. Furthermore
we did not only show that with increasing NYHA
functional class the number of CD34+ and
CD34+/CD133+ decreased but that there is a nega-
tive correlation between NYHA functional class and
the number of CD34+/CD133+ cells in CAD pa-
tients and the number of CD34+ and
CD34+/CD133+ cells in no CAD patients.
The third important result is that the number of
CD133+ cells is only affected by age and not by heart
failure. This is interesting because CD133 marks the
most primitive circulating progenitor cells [14]. The
function of the early haematopoietic stem cells mark-
er CD133 is not known. Using CD133 expression to
define a very early subset of progenitor cells Peichev
et al. [15] isolated a subpopulation which was able to
differentiate into mature endothelial cells. Further-
more CD133+ cells of the bone marrow have been
shown to have endothelial character and may con-
tribute to neoangiogenesis [16].
Taking under consideration that Heeschen et al.
[17] found no difference between the number of
CD34+ and CD34+/CD133+ cells in the bone mar-
row in healthy controls and patients with ischemic car-
diomyopathy we speculate that in CHF the release of
CD34+, CD133+ and CD34+/CD133+ cells is dif-
ferently affected by CHF. The mechanism responsible
for this different regulation of progenitor cell release
is not explained so far. An increased tumor necrosis
factor (TNF)α concentration which is found in CHF
may be responsible [12]. An animal study suggested
that TNFα might increase apoptosis of progenitor
cells in the bone marrow of mice with ischemic heart
failure [18]. So far neither the exact mechanism of dif-
ferential regulation of different CPC subsets is not
known nor the biological meaning of this observation.
A recently published study by Geft et al. showed that
not only the number of CD34+ cells are decreased by
increasing NYHA functional class but in moderate to
severe heart failure the number of irreversible apop-
totic CD34+ cells were significantly increased [19].
LIMITATIONS OF THE STUDY
There are some limitations of our study. One is that
we have a significant younger contol group. But the
fact that we found different numbers of CD34+,
CD133+ and CD34/CD133+ cells in CHF is inde-
pendent of a control group. We can not exclude that
in moderate CHF the number of CD34+, CD133+
and CD34/CD133+ cells are higher than in an aged
matched control group as shown by Valgimigli et al.
[12] but the fact that the number of these cells is regu-
lated in a different manner in CHF is not affected.
A further limitation is that statin treatment is higher
in NYHA III and IV than in NYHA I and II. Because
statines cause mobilisation of EPC [16] the observed
decreased number of CD34+ and CD133+ cells should
be much lower without statin treatment and therefore
the measured effect is under- than overestimated. Be-
cause smoking also reduces EPC number the here pre-
sented differential number of CD34+, CD133+ and
CD34/CD133+ cells is underestimated in lower
NYHA classes because of the higher number of smok-
ers in NYHA I and II compared to NYHA III and IV.
We also did not measure the concentration of
known cytokines influencing endothelial progenitor
cell number. However this was done by several studies
measuring and correlating EPC number with the con-
centration of this cytokines [11, 12, 13, 20].
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